Veradermics, Inc APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Veradermics, Inc (MANE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Veradermics, Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.52M, a 2957.39% increase year-over-year.
- Veradermics, Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.26M, a 2369.01% increase year-over-year.
- Veradermics, Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $115.00K.
- Veradermics, Inc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $213.00K.
- Veradermics, Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.44M, a 476.00% increase from fiscal 2024.
- Veradermics, Inc apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $250.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|
| 2026-06-30 | $3.52M 10-Q · filed 2026-08-11 | $8.78M derived: sum of 2 quarters · filed 2026-08-11 | |
| 2026-03-31 | $5.26M 10-Q · filed 2026-08-11 | ||
| 2025-12-31 | $1.44M 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $115.00K 10-Q · filed 2026-08-11 | $328.00K derived: sum of 2 quarters · filed 2026-08-11 | |
| 2025-03-31 | $213.00K 10-Q · filed 2026-08-11 | ||
| 2024-12-31 | $250.00K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |